Predictors of loss of asthma control in the Phase 2a INCONTRO trial: A post-hoc analysis

2020 ◽  
Author(s):  
Robert Palmér ◽  
Joachim Almquist ◽  
Mahdi Hashemi ◽  
Ziad Taib ◽  
Sofia Necander ◽  
...  
Keyword(s):  
Asthma Control ◽  
Post Hoc Analysis ◽  
Post Hoc

Application of machine learning algorithms to predict loss of asthma control: A post-hoc analysis of INCONTRO study

2020 ◽  
Author(s):  
Sofia Necander ◽  
Ana Teixeira ◽  
Vaishali Chaudhuri ◽  
Mahdi Hashemi ◽  
Robert Pálmer ◽  
...  
Keyword(s):  
Machine Learning ◽  
Asthma Control ◽  
Learning Algorithms ◽  
Machine Learning Algorithms ◽  
Post Hoc Analysis ◽  
Post Hoc

scholarly journals Linkage of Maternal Caregiver Smoking Behaviors on Environmental and Clinical Outcomes of Children with Asthma: A Post-Hoc Analysis of a Financial Incentive Trial Targeting Reduction in Pediatric Tobacco Smoke Exposures

2020 ◽  
Vol 17 (22) ◽  
pp. 8502
Author(s):  
Mandeep S. Jassal ◽  
Cassia Lewis-Land ◽  
Richard E. Thompson ◽  
Arlene Butz
Keyword(s):  
Clinical Outcomes ◽  
Asthma Control ◽  
Tobacco Smoke ◽  
Anxiety And Depression ◽  
Total N ◽  
Post Hoc Analysis ◽  
High Category ◽  
Smoking Behaviors ◽  
Caregiver Anxiety ◽  
Post Hoc

(1) Background: Monthly variability in smoking behaviors in caregivers of pediatric asthmatics yields questions of how much and when does smoking reduction result in improved environmental and clinical outcomes. (2) Methods: Post hoc analysis of data from a 6 month pilot randomized-control trial occurring from May 2017 to May 2018 in Baltimore City (MD, USA). The initial trial’s primary intervention explored the utility of financial incentives in modifying caregiver smoking behaviors. Post hoc analyses examined all dyads independent of the initial trial’s randomization status. All caregivers received pediatric tobacco smoke harm reduction education, in addition to monthly encouragement to access the state tobacco quitline for individual phone-based counseling and nicotine replacement therapy. Maternal caregivers who were active cigarette smokers and their linked asthmatic child (aged 2–12 years) were grouped into two classifications (“high” versus “low”) based on the child and caregiver’s cotinine levels. A “low” cotinine level was designated by at least a 25% reduction in cotinine levels during 3 months of the trial period; achieving ≤2 months of low cotinine levels defaulted to the “high” category. Twenty-seven dyads (caregivers and children) (total n = 54) were assigned to the “high” category, and eighteen dyads (caregivers and children) (total n = 36) were allocated to the “low” category. The primary outcome measure was the correlation of caregiver cotinine levels with pediatric cotinine values. Secondary outcomes included asthma control, in addition to caregiver anxiety and depression. (3) Results: Caregivers with 3 months of ≥25% decrease in cotinine levels had a significantly greater mean change in child cotinine levels (p = 0.018). “Low” caregiver cotinine levels did not significantly improve pediatric asthma control (OR 2.12 (95% CI: 0.62–7.25)). Caregiver anxiety and depression outcomes, measured by Patient Health Questionnaire (PHQ)-4 scores, was not significantly different based on cotinine categorization (p = 0.079); (4) Conclusion: Reduced pediatric cotinine levels were seen in caregivers who reduced their smoking for at least 3 months, but clinical outcome measures remained unchanged.

scholarly journals Asthma control using fluticasone propionate/salmeterol in Asian and non-Asian populations: a post hoc analysis of the GOAL study

2017 ◽  
Vol 17 (1) ◽  
Author(s):  
Jean Bousquet ◽  
Neil Barnes ◽  
Michael Gibbs ◽  
Nadeem Gul ◽  
Susan A Tomkins ◽  
...  
Keyword(s):  
Fluticasone Propionate ◽  
Asthma Control ◽  
Post Hoc Analysis ◽  
Asian Populations ◽  
Post Hoc

scholarly journals Efficacy of one time per day, single-inhaler indacaterol/glycopyrronium/mometasone in patients with inadequately controlled asthma: post hoc analysis of IRIDIUM study in Asian population

2021 ◽  
Vol 8 (1) ◽  
pp. e000856 ◽  
Author(s):  
Hironori Sagara ◽  
Nathalie Barbier ◽  
Tsuyoshi Ishii ◽  
Hajime Yoshisue ◽  
Ivan Nikolaev ◽  
...  
Keyword(s):  
Lung Function ◽  
Asthma Control ◽  
Inhaled Corticosteroids ◽  
High Dose ◽  
Asthma Control Questionnaire ◽  
Post Hoc Analysis ◽  
Asian Patients ◽  
Asthma Exacerbations ◽  
Post Hoc ◽  
Medium Dose

Background and objectiveThe 52-week IRIDIUM study demonstrated the efficacy of indacaterol acetate/glycopyrronium bromide/mometasone furoate (IND/GLY/MF) versus IND/MF and salmeterol xinafoate/fluticasone propionate (SAL/FLU) in patients with symptomatic asthma, despite long-acting β2-agonist/inhaled corticosteroids (LABA/ICS) medium-dose or high-dose, predicted forced expiratory volume in 1 s (FEV1) <80% and at least one exacerbation in the previous year. Here, we present data from a post hoc analysis of the IRIDIUM study in the Asian subpopulation.MethodsThis post hoc analysis evaluated improvements in lung function, asthma control and reduction in asthma exacerbations with IND/GLY/MF medium- (150/50/80 µg) and high-dose (150/50/160 µg) versus IND/MF medium- (150/160 µg) and high-dose (150/320 µg), all one time per day and SAL/FLU high-dose (50/500 µg) two times per day, in Asian patients from the IRIDIUM study.ResultsIn total, 258 patients (IND/GLY/MF medium-dose, 52; IND/GLY/MF high-dose, 52; IND/MF medium-dose, 51; IND/MF high-dose, 51; SAL/FLU high-dose, 52) were included. IND/GLY/MF medium- and high-dose showed greater improvement in trough FEV1 at week 26 versus respective doses of IND/MF (Δ, 100 mL and 101 mL; both p<0.05, respectively), and SAL/FLU high-dose (Δ, 125 mL; p=0.0189, and 136 mL; p=0.0118, respectively), which were maintained over 52 weeks. Both doses of IND/GLY/MF showed greater improvement in morning and evening peak expiratory flow versus respective doses of IND/MF and SAL/FLU high-dose at week 52. The changes in Asthma Control Questionnaire-7 scores from baseline were comparable in all treatment groups. IND/GLY/MF medium- and high-dose showed greater reductions in severe (34%, 69%), moderate or severe (18%, 54%) and all exacerbations (21%, 34%) compared with SAL/FLU high-dose over 52 weeks.ConclusionOne time per day, single-inhaler IND/GLY/MF improved lung function, reduced asthma exacerbations and provided comparable asthma control versus IND/MF and SAL/FLU in Asian patients with inadequately controlled asthma despite LABA/ICS. The results of this analysis were consistent with the overall population in the IRIDIUM study.

Abstract #295 GLP-1 Receptor Agonists and Death From Any Cause in Elderly Patients with Type 2 Diabetes Mellitus: A Post-Hoc Analysis

2018 ◽  
Vol 24 ◽  
pp. 80-81
Author(s):  
Konstantinos Toulis ◽  
Krishna Gokhale ◽  
G. Neil Thomas ◽  
Wasim Hanif ◽  
Krishnarajah Nirantharakumar ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Elderly Patients ◽  
Post Hoc Analysis ◽  
Receptor Agonists ◽  
Post Hoc
Sign in / Sign up

Export Citation Format

Share Document